You are here

Saracatinib Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition

The FDA has awarded orphan drug status to AstraZeneca’s AZD0530 (Saracatinib), a potential new drug for the treatment of idiopathic pulmonary fibrosis (IPF).

IPF, a chronic, progressive, irreversible, and typically fatal interstitial lung disease, affects approximately 100,000 people in the U.S. Patients with IPF generally live between two and five years from diagnosis, as there are few medicines available for treating the disease. 

Pre-clinical trials of AZD0530 showed that it inhibits fibroblast activity and collagen deposition, which are key features of lung fibrosis.

AZD0530 is a small molecule, highly potent, selective inhibitor of src tyrosine kinase, which regulates broad cell functions including cell growth and cell differentiation. Phase 2 trials for AZD0530 in IPF have not yet commenced.

Source: AstraZeneca, March 18, 2019

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Drug Improved or Stabilized Symptoms, Shrank Brain Lesions